PMCB

PHARMACYTE BIOTECH, INC.

PMCB · CIK 1157075 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$0M
20182025
Net Income$31M
20182025
Operating CF−$3M
20182025
Free Cash Flow
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Net Income$0.0B$0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$3.19$-1.80$-0.22$-0.27————
EPS (Diluted)$3.19$-1.80$-0.22$-0.27————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Current Assets$0.0B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Cash & Equivalents$0.0B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.0B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$-0.0B$-0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Capital Expenditures————————
Financing Cash Flow$-0.0B$-0.0B$-0.0B$0.1B$0.0B$0.0B$0.0B$0.0B
← Companies